No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ABBV AbbVie
- 167.290
- -0.510-0.30%
Close Apr 25 16:00 ET
- 168.970
- +1.680+1.00%
Pre 04:51 ET
296.21BMarket Cap61.50P/E (TTM)
169.290High165.570Low5.50MVolume167.660Open167.800Pre Close919.87MTurnover0.31%Turnover Ratio61.50P/E (Static)1.77BShares181.19652wk High28.59P/B294.67BFloat Cap125.84752wk Low5.92Dividend TTM1.76BShs Float181.196Historical High3.54%Div YieldTTM2.22%Amplitude20.362Historical Low167.138Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Alphabet, Microsoft, Intel, Snap, Meta, Exxon, Chevron, and More Stock Market Movers
Alphabet shares surge after Google's parent posts better-than-expected earnings and announces its first cash dividend, Microsoft posts 31% quarterly growth in Azure cloud-computing revenue, and Snap soars after issuing a strong forecast for second-quarter sales. Earnings are scheduled Friday from Exxon Mobil and Chevron.
PCE Inflation Data, ExxonMobil, Earnings: What to Watch
Express News | Cigna Says Biosimilar to Abbvie's Humira Will Be Available Through Agreements With Multiple Manufacturers
Cigna to Offer Humira Rivals With $0 Copay at Specialty Pharmacy
Express News | NYSE Order Imbalance 131290.0 Shares on Buy Side
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Thursday, AbbVie Inc (NASDAQ:ABBV) released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study of upadacitinib (Rinvoq, 15 mg once daily starting dos
Comments
My trading plan for April 2024 to July 2024.
Hello Mooers! 
Recently, there have been signs that World War 3
is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task.
In light of this hypothetical situation
, I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy. 
Approach One: Buy the winners
Who are the winners? During wars, companies that are in the defense, oil, ...
Recently, there have been signs that World War 3
is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task. In light of this hypothetical situation
, I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy. Approach One: Buy the winnersWho are the winners?
During wars, companies that are in the defense, oil, ...
28
29
$Novo-Nordisk A/S(NVO.US$ & $Eli Lilly and Co(LLY.US$ 's MCap increased by $285 bil in Q1 2024 alone, driven mostly by growth of the GLP-1 franchises,
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...
4
Major acquisition announced YTD in 2024
A look at one of the major acquisition deals YTD…👇
$MRTX
Acquired By: Bristol-Myers Squibb$Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$$GlaxoSmithKline(GSK.US$
$MRTX
Acquired By: Bristol-Myers Squibb$Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$$GlaxoSmithKline(GSK.US$
4
1
🔥 M&A News 🔥
$AbbVie(ABBV.US$ to acquire $Landos Biopharma(LABP.US$
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)
$Nuvation Bio(NUVB.US$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)
$Novo-Nordisk A/S(NVO.US$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pi...
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)
$Nuvation Bio(NUVB.US$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)
$Novo-Nordisk A/S(NVO.US$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pi...
11
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Money Thrill : Instead of cash (cash is ONLY an paper without underlying value ! ) I buyed Amundi PHYSICAL GOLD ETC . Friday up 0.37 % ... and in 14 days 7 %. Chinese gouvernement buyed a lot of gold! LESSON > MONEY has only a Value because the COMMON TRUST in this PAPER. [Money Printing presses can make more] On the other hand, shares also have an intrinsic value better than paper money. Then choose the right one if war breaks out
Mars MoooOP Money Thrill:
profitpilot : Hold and observe. Don't buy the dip just because it's cheap. Cheap can be cheaper. Time the market (as best as you can).
Mars MoooOP profitpilot:
Cui Nyonya Kueh :
View more comments...